295 related articles for article (PubMed ID: 21479639)
1. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.
Alpizar YA; Chain B; Collins MK; Greenwood J; Katz D; Stauss HJ; Mitchison NA
Cancer Immunol Immunother; 2011 Aug; 60(8):1127-35. PubMed ID: 21479639
[TBL] [Abstract][Full Text] [Related]
2. [The immune system - how does anti-tumor immunity arise ?].
Sankawa Y
Oncol Res Treat; 2014; 37 Suppl 4():2-5. PubMed ID: 25301189
[No Abstract] [Full Text] [Related]
3. Signaling defects in anti-tumor T cells.
Frey AB; Monu N
Immunol Rev; 2008 Apr; 222():192-205. PubMed ID: 18364003
[TBL] [Abstract][Full Text] [Related]
4. Immunology in tumor therapeutics: an overview.
Barber HR
Del Med J; 1980 Apr; 52(4):197-209. PubMed ID: 6153996
[No Abstract] [Full Text] [Related]
5. Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.
Phan TG; Long GV; Scolyer RA
Immunol Cell Biol; 2015 Apr; 93(4):323-5. PubMed ID: 25686808
[No Abstract] [Full Text] [Related]
6. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
7. Current immunotherapy for solid tumors.
Barkholt L; Bregni M
Immunotherapy; 2009 May; 1(3):483-93. PubMed ID: 20635964
[TBL] [Abstract][Full Text] [Related]
8. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
9. Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
Khong HT; Restifo NP
Nat Immunol; 2002 Nov; 3(11):999-1005. PubMed ID: 12407407
[TBL] [Abstract][Full Text] [Related]
10. Why current peptide-based cancer vaccines fail: lessons from the three Es.
Claesson MH
Immunotherapy; 2009 Jul; 1(4):513-6. PubMed ID: 20635981
[No Abstract] [Full Text] [Related]
11. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
12. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
13. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.
Van Waes C; Monach PA; Urban JL; Wortzel RD; Schreiber H
Tissue Antigens; 1996 May; 47(5):399-407. PubMed ID: 8795140
[TBL] [Abstract][Full Text] [Related]
14. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
Fritsch EF; Burkhardt UE; Hacohen N; Wu CJ
Cancer Immunol Res; 2020 Dec; 8(12):1465-1469. PubMed ID: 33262163
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
16. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.
Coughlin CM; Vance BA; Grupp SA; Vonderheide RH
Blood; 2004 Mar; 103(6):2046-54. PubMed ID: 14630810
[TBL] [Abstract][Full Text] [Related]
17. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Grenier JM; Yeung ST; Khanna KM
Front Immunol; 2018; 9():610. PubMed ID: 29623082
[TBL] [Abstract][Full Text] [Related]
18. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
19. Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?
Pawelec G
Cancer Immunol Immunother; 1999 Oct; 48(7):343-5. PubMed ID: 10501845
[No Abstract] [Full Text] [Related]
20. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
